CA3160181A1 - Novel ddr1 antibodies and uses thereof - Google Patents

Novel ddr1 antibodies and uses thereof Download PDF

Info

Publication number
CA3160181A1
CA3160181A1 CA3160181A CA3160181A CA3160181A1 CA 3160181 A1 CA3160181 A1 CA 3160181A1 CA 3160181 A CA3160181 A CA 3160181A CA 3160181 A CA3160181 A CA 3160181A CA 3160181 A1 CA3160181 A1 CA 3160181A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
variable region
acid sequence
ddr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3160181A
Other languages
English (en)
French (fr)
Inventor
Ningyan Zhang
Zhiqiang An
Hui Deng
Xiujie SUN
Rong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
The University of Texas System
Original Assignee
George Washington University
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Washington University, The University of Texas System filed Critical George Washington University
Publication of CA3160181A1 publication Critical patent/CA3160181A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3160181A 2019-12-17 2020-12-17 Novel ddr1 antibodies and uses thereof Pending CA3160181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949300P 2019-12-17 2019-12-17
US62/949,300 2019-12-17
PCT/US2020/065618 WO2021127185A1 (en) 2019-12-17 2020-12-17 Novel ddr1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3160181A1 true CA3160181A1 (en) 2021-06-24

Family

ID=76478553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3160181A Pending CA3160181A1 (en) 2019-12-17 2020-12-17 Novel ddr1 antibodies and uses thereof

Country Status (10)

Country Link
US (2) US20230130372A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076526A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023508277A (cg-RX-API-DMAC7.html)
CN (1) CN115443150A (cg-RX-API-DMAC7.html)
AU (1) AU2020407089B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011037A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160181A1 (cg-RX-API-DMAC7.html)
IL (1) IL294019A (cg-RX-API-DMAC7.html)
MX (1) MX2022007353A (cg-RX-API-DMAC7.html)
WO (1) WO2021127185A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230235078A1 (en) * 2019-12-17 2023-07-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116023497B (zh) * 2022-11-09 2024-06-21 四川大学华西医院 抗ddr1抗体及其用途
EP4619441A1 (en) * 2022-11-16 2025-09-24 Incendia Therapeutics, Inc. Methods of treating cancer using anti-ddr1 antibodies
EP4619442A1 (en) * 2022-11-16 2025-09-24 Incendia Therapeutics, Inc. Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors
CN118909125B (zh) * 2024-10-10 2025-01-03 杭州美赛生物医药科技有限公司 抗ddr1抗体及其应用
WO2026117608A2 (en) * 2024-11-26 2026-06-04 Immunome, Inc. Immunoconjugates for ddr1 and methods of use

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051397A (en) 1993-11-16 2000-04-18 Max Planck Gesellschaft Zur Forderung Der Wissenschaften DNA encoding MCK-10, a novel receptor tyrosine kinase
US20020115173A1 (en) 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
WO2003082328A1 (en) 2002-03-12 2003-10-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of discoidin domain receptor 1 (ddr1) and agents that affect the ddr1/collagen pathway
JP2005521420A (ja) 2002-04-03 2005-07-21 エージーワイ セラピューティクス インコーポレイティッド 脳腫瘍の処置及び可視化における生体分子標的の使用法
US20070025997A1 (en) 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
US20100166731A1 (en) 2005-09-30 2010-07-01 Bartz Steven R Methods and Compositions for Treating Cancer
EP1992347A1 (en) 2007-05-18 2008-11-19 Cellzome Ag Treatment of DDR1 positive cancer using imatinib
WO2010019702A2 (en) * 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
JP5985481B2 (ja) 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗イディオタイプ抗体の迅速な産生
EP2659269B1 (en) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
ES2785081T3 (es) * 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
JP6101205B2 (ja) * 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ddr1抗体
GB201115529D0 (en) * 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013113615A1 (en) 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
AR092662A1 (es) * 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
WO2014140330A1 (en) 2013-03-15 2014-09-18 Oryzon Genomics, S.A. Anti-ddr1 internalizing antibodies and their medical use
KR102113310B1 (ko) 2013-09-03 2020-05-20 아주대학교 산학협력단 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법
US20160251440A1 (en) 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2015116569A2 (en) * 2014-01-30 2015-08-06 Anaptysbio, Inc. Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
CN115414480A (zh) 2014-11-10 2022-12-02 德玛医药 结合放射用于治疗非小细胞肺癌和多形性胶质母细胞瘤的二去水卫矛醇
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ, インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
KR20180007924A (ko) 2016-07-14 2018-01-24 주식회사 코리아하이텍 차량용 빔프로젝터 방열 장치
BR112019010002A2 (pt) * 2016-12-16 2019-08-20 Merck Patent Gmbh métodos para o uso de proteína de ligação galectina-3 detectada na urina para monitoramento da gravidade e progressão da nefrite lúpica
AU2018204986B2 (en) * 2017-01-02 2024-08-01 The Board Of Regents Of The University Of Texas System Anti-LAIR1 antibodies and their uses
EP3592384B1 (en) * 2017-03-09 2025-07-02 MAB Discovery GmbH Antibodies specifically binding to human il-1r7
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
KR20210125094A (ko) 2017-04-06 2021-10-15 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3067835A1 (en) * 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
EP3655961A4 (en) 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7262817B2 (ja) 2017-12-31 2023-04-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 分岐連結体を備えたチューブリシン類縁体の共役体
WO2019243431A1 (en) 2018-06-20 2019-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating melanoma
MX2020014083A (es) 2018-07-05 2021-04-12 Hangzhou Dac Biotech Co Ltd Un derivado de dímero de pirrolobenzodiazepina (pbd) reticulado y sus conjugados.
WO2020046770A1 (en) 2018-08-31 2020-03-05 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Kinase activity in tumors
US20230010108A1 (en) 2018-10-12 2023-01-12 Hangzhou Dac Biotech Co., Ltd. A conjugation linker containing 2,3-diaminosuccinyl group
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
CA3128264A1 (en) 2019-01-31 2020-08-06 Hangzhou Dac Biotech Co., Ltd A conjugate of an amanita toxin with branched linkers
JP2022544442A (ja) 2019-06-24 2022-10-19 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. チューブリシン類縁体と細胞結合分子との共役体の製剤
CA3144784A1 (en) 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
US20230093080A1 (en) 2019-07-15 2023-03-23 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP4053157A4 (en) 2019-11-01 2023-12-27 Cellemedy Co., Ltd PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE
JP7541390B2 (ja) 2019-11-01 2024-08-28 セレメディー カンパニー,リミテッド 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
EP4076526A4 (en) * 2019-12-17 2024-07-03 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
PH12022500032A1 (en) 2020-06-19 2024-02-26 Hangzhou Dac Biotech Co Ltd Conjugates of a cell-binding molecule with camptothecin analogs
IL302037A (en) 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic heterobifunctional compounds for degradation of targeted proteins
US20230391893A1 (en) 2020-10-30 2023-12-07 Cellemedy Co.,Ltd Antibody-like protein and use thereof
WO2022135332A1 (zh) 2020-12-21 2022-06-30 映恩生物制药(苏州)有限公司 一种甾体偶联物
CN114807042B (zh) 2021-01-22 2024-09-03 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
WO2022171101A1 (zh) 2021-02-10 2022-08-18 映恩生物制药(苏州)有限公司 一种甾体偶联物
NL2028075B1 (en) 2021-04-26 2022-11-03 Alphathera Ag Targeting system for cancer comprising a radioisotope
US20240216517A1 (en) 2021-05-03 2024-07-04 Cellemedy Co., Ltd Pharmaceutical composition for prevention or treatment of lung cancer
CN119039440A (zh) 2021-07-02 2024-11-29 来凯医药科技(上海)有限公司 活化的肝星状细胞(hsc)的消耗及其用途
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス(スーチョウ)カンパニー,リミティド ステロイド化合物及びそのコンジュゲート
US20250179114A1 (en) 2021-09-14 2025-06-05 Duality Biologics (Suzhou) Co., Ltd. Anti-Inflammatory Compound and Use Thereof
JP2024536840A (ja) 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Il-2バリアント及びその融合タンパク質
WO2023061478A1 (zh) 2021-10-15 2023-04-20 先声再明医药有限公司 三环类化合物
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
WO2023163873A1 (en) 2022-02-23 2023-08-31 Mayo Foundation For Medical Education And Research Synergistic drug combinations to treat cancer
WO2023160721A1 (en) 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230235078A1 (en) * 2019-12-17 2023-07-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
US12331130B2 (en) * 2019-12-17 2025-06-17 The Board Of Regents Of The University Of Texas System DDR1 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2023508277A (ja) 2023-03-02
EP4076526A4 (en) 2024-07-03
CN115443150A (zh) 2022-12-06
AU2020407089A1 (en) 2022-06-30
US20230235078A1 (en) 2023-07-27
JP7883266B2 (ja) 2026-07-01
US20230130372A1 (en) 2023-04-27
BR112022011037A2 (pt) 2022-09-13
EP4076526A1 (en) 2022-10-26
MX2022007353A (es) 2022-09-19
IL294019A (en) 2022-08-01
WO2021127185A1 (en) 2021-06-24
US12331130B2 (en) 2025-06-17
JP2024164067A (ja) 2024-11-26
AU2020407089B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11498963B2 (en) Anti-LILRB antibodies and their use in detecting and treating cancer
US20250250336A1 (en) Novel lilrb4 antibodies and uses thereof
US12331130B2 (en) DDR1 antibodies and uses thereof
US11377491B2 (en) Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
US20230139944A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
US20240294670A1 (en) Antibodies to chitinase 3-like-1 and methods of use therefor
US20230399384A1 (en) Antibodies to coronavirus spike protein and methods of use thereof
US20220144926A1 (en) Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
US20240085427A1 (en) AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER
EA048483B1 (ru) Новые антитела ddr1 и их применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241121

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241121

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250609

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250609

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250609

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250613

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202